Scynexis bids to end novel antifungal drought, filing ibrexafungerp in USScynexis has filed for FDA approval of its novel drug ibrexafungerp which – if approved – would be Share XScynexis bids to end novel antifungal drought, filing ibrexafungerp in UShttps://pharmaphorum.com/news/scynexis-bids-to-end-novel-antifungal-drought/
Final Reminder: 1 Week Until SMi’s Superbugs & Superdrugs Conference USA12 – 13 November 2018 Iselin, New Jersey www.superbugs-usa.com/press Sponsored by Scynexis The issue of antibacterial resistance is Share XFinal Reminder: 1 Week Until SMi’s Superbugs & Superdrugs Conference USAhttps://pharmaphorum.com/partner-content/final-reminder-1-week-until-smis-superbugs-superdrugs-conference-usa/
Antibiotic Class Emerges through Digestive EnzymeDrug-resistant organisms kill an estimated 23,000 people in the U.S. every year, and it is predicted that by Share XAntibiotic Class Emerges through Digestive Enzymehttps://pharmaphorum.com/partner-content/antibiotic-class-emerges-through-digestive-enzyme/
